PA
TVTX icon

PharVision Advisers’s Travere Therapeutics TVTX Stock Holding History

PharVision Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,799
Closed -$210K – 1013
2025
Q3 		$210K Buy
+8,799
New +$165K 0.12% 475

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PharVision Advisers's TVTX Position: Q4 2025 in Review

PharVision Advisers sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 8,799 shares — an estimated $210K sold.

PharVision Advisers first reported a position in TVTX in Q3 2025 and held it in 1 quarter. The position peaked at $210K in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • PharVision Advisers reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 8,799 Travere Therapeutics shares in Q4 2025, an estimated $210K.
  • PharVision Advisers first reported a position in Travere Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Travere Therapeutics position peaked at $210K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.